首页> 外文期刊>BMC Cancer >Infiltration of CD1a-positive dendritic cells in advanced laryngeal cancer correlates with unfavorable outcomes post-laryngectomy
【24h】

Infiltration of CD1a-positive dendritic cells in advanced laryngeal cancer correlates with unfavorable outcomes post-laryngectomy

机译:晚期喉癌中CD1A阳性树突细胞的浸润与喉后切除后的不利结果相关

获取原文
       

摘要

The prognosis of advanced laryngeal cancer is unfavorable despite advances in multidisciplinary therapy. Dendritic cells (DCs) play a central role in antitumor immunity. Tumor-infiltrating CD1a DCs have been reported to be associated with clinical outcomes in carcinomas of various organs, but the clinical impact of CD1a DCs in laryngeal cancer remains to be unequivocally established. We retrospectively analyzed the cases of 57 patients with Stage III or IV laryngeal cancer who underwent a total laryngectomy. Immunohistochemistry detection of CD1a, S100 and CD8 was performed on representative resected specimens. CD1a DCs, S100 DCs and CD8 cytotoxic T-lymphocytes (CTLs) were evaluated, and the cases divided into high and low groups according to the cut-off of the median values for each of these 3 parameters. Compared to the CD1a-low group, the CD1a-high group had more advanced cases and showed significantly worse disease-specific survival (DSS) (P?=?0.008) and overall survival (OS) (P?=?0.032). The analyses of S100 DCs and CD8 CTLs revealed no significant impact on clinical outcomes. However, multivariate analysis revealed that infiltration of CD1a DCs was an independent unfavorable prognostic factor for both DSS (P?=?0.009) and OS (P?=?0.013). Our results demonstrated that the infiltration of CD1a DCs was associated with unfavorable clinical outcomes in patients with advanced laryngeal cancer who underwent a total laryngectomy as the initial treatment.
机译:尽管多学科疗法进展,但晚期喉癌的预后是不利的。树突状细胞(DCS)在抗肿瘤免疫中起着中心作用。据报道,肿瘤浸润的CD1A DCS与各种器官的癌症中的临床结果相关,但CD1A DC在喉癌中的临床影响仍然明确地建立。我们回顾性地分析了57例III阶段或IV喉癌患者的患者,他们接受了总喉切除术。对代表切除的标本进行CD1A,S100和CD8的免疫组化检测。评估CD1A DCS,S100 DCS和CD8细胞毒性T淋巴细胞(CTL),并且根据这3个参数中的每一个的中值值的切断,分为高低组。与CD1A-LOW组相比,CD1A-HIGH组具有更先进的病例,并且表现出显着更差的疾病特异性存活(DSS)(P?= 0.008)和整体存活(OS)(P?= 0.032)。 S100 DCS和CD8 CTL的分析显示对临床结果没有显着影响。然而,多变量分析显示CD1A DCS的浸润是DSS(P?= 0.009)和OS(P?= 0.013)的独立不利的预后因素。我们的结果表明,CD1A DCS的浸润与晚期喉癌患者的不利临床结果有关,患有喉切切除术作为初始治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号